Tracqui A, Tournoud C, Flesch F, Kopferschmitt J, Kintz P, Deveaux M, Ghysel M H, Marquet P, Pépin G, Petit G, Jaeger A, Ludes B
Institut de Médecine Lègale, Strasbourg.
Presse Med. 1998 Mar 28;27(12):557-61.
Buprenorphine has been an important advance in care for drug abusers, but the toxic risk may be fatal. We report here two original series of buprenorphine poisoning in opiate abusers on substitution therapy.
The first series included 20 males and 9 females, aged 20-35 years (mean = 27.5) with non-fatal poisoning. The second series included 20 subjects (19 males, 1 female) aged 14-48 years (mean = 26.6) with a fatal outcome. All subjects were opiate addicts taking high-dosage sublingual buprenorphine formulation as substitution therapy.
Blood concentrations of buprenorphine were found in all cases to remain at a low level (1.0-2.3 ng/ml, m = 1.4 ng/ml, and 1.1-29.0 ng/ml, m = 8.4 ng/ml in non-fatal and fatal cases respectively). Almost all cases involved concomitant intake of psychotropic medications, especially benzodiazepines (18 non-fatal and 17 fatal cases).
These observations confirm previously reported data on the danger of buprenorphine-benzodiazepine combinations. Intravenous injection of crushed tablets also appears to be a risk factor (8 deaths and 10 non-fatal poisonings). This series highlights the need for improvement in the recently developed French program for substitution therapy with high-dosage buprenorphine in heroin addicts.
丁丙诺啡在药物滥用者的治疗中是一项重要进展,但中毒风险可能致命。我们在此报告两例阿片类药物滥用者接受替代治疗时丁丙诺啡中毒的原始病例系列。
第一个病例系列包括20名男性和9名女性,年龄在20至35岁之间(平均27.5岁),为非致命性中毒。第二个病例系列包括20名受试者(19名男性,1名女性),年龄在14至48岁之间(平均26.6岁),结果为致命。所有受试者均为阿片类药物成瘾者,正在接受高剂量舌下丁丙诺啡制剂作为替代治疗。
在所有病例中均发现丁丙诺啡血药浓度处于低水平(非致命病例中为1.0 - 2.3纳克/毫升,中位数为1.4纳克/毫升;致命病例中为1.1 - 29.0纳克/毫升,中位数为8.4纳克/毫升)。几乎所有病例都同时摄入了精神药物,尤其是苯二氮䓬类药物(非致命病例18例,致命病例17例)。
这些观察结果证实了先前报道的关于丁丙诺啡 - 苯二氮䓬类药物联合使用危险性的数据。静脉注射碾碎的药片似乎也是一个危险因素(8例死亡和10例非致命性中毒)。该病例系列凸显了对法国最近为海洛因成瘾者制定的高剂量丁丙诺啡替代治疗方案进行改进的必要性。